Latest Conference Articles

November 26th 2019, 11:23pm

SMR Congress

Ryan J. Sullivan, MD, discusses the rationale for BRAF/MEK combinations and immunotherapeutic combinations in melanoma and ongoing research examining triplet regimens.

November 26th 2019, 8:12pm

SMR Congress

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the findings from a subgroup analyses of the CheckMate-067 trial.

November 26th 2019, 4:33am

State of the Science Summit on Genitourinary Cancers

Eric Shinohara, MD, MSCI, discusses the emergence of stereotactic body radiotherapy to treat patients with prostate cancer.

November 25th 2019, 9:43pm

SMR Congress

The combination of cobimetinib (Cotellic) and vemurafenib (Zelboraf) maintained an advantage for overall survival and objective response rate in patients with BRAF-positive melanoma versus vemurafenib alone.

November 24th 2019, 4:00pm

SMR Congress

Patients with unresectable or metastatic BRAF V600-mutant melanoma who achieve a complete response to dabrafenib (Tafinlar) plus trametinib (Mekinist) are more likely to have improved survival outcomes at 5 years.

November 24th 2019, 3:07am

SMR Congress

Isabella C. Glitza, MD, discusses a single-center phase I/Ib trial of concurrent intravenous and intrathecal nivolumab for patients with metastatic melanoma and leptomeningeal disease.

November 23rd 2019, 11:45pm

SMR Congress

Grant McArthur, PhD, discusses significant results from the final analysis of the coBRIM trial, which evaluated the 5-year survival data of cobimetinib plus vemurafenib in patients with BRAF V600-mutated advanced melanoma.

November 23rd 2019, 8:05pm

SMR Congress

Talimogene laherparepvec (T-VEC; Imlygic) prior to surgery was associated with improved recurrence-free survival and overall survival compared with surgery alone in patients with resectable advanced melanoma.

November 23rd 2019, 3:47am

SMR Congress

Ryan J. Sullivan, MD, discusses the significance of the BRAF/MEK combination dabrafenib and trametinib, which was the first BRAF/MEK inhibitor regimen to be approved by the FDA for the treatment of patients with BRAF V600E–positive stage III melanoma following complete resection.

November 23rd 2019, 2:51am

SMR Congress

Adil Daud, MD, discusses the role of dabrafenib plus trametinib in patients with advanced melanoma and highlighted other combinations under investigation.

November 23rd 2019, 1:13am

SMR Congress

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a sustained survival benefit compared with nivolumab or ipilimumab alone, according to 5-year follow-up results.

November 22nd 2019, 8:10am

SMR Congress

Gaudenz Danuser, PhD, discusses how the activation of RacP29S impacts the treatment of patients with melanoma. His lab has been studying the Rac molecule for around 20 years. The RacP29S mutation most commonly appears in melanoma, but it has since been discovered in a few other cancer types as well.

November 22nd 2019, 3:28am

SMR Congress

Combining a BRAF inhibitor with a MEK inhibitor causes endoplasmic reticulum stress in BRAF wild-type, NRAS­-mutated melanoma cells, resulting in significant antitumor activity.

November 22nd 2019, 3:11am

State of the Science Summit on Genitourinary Cancers

David F. Penson, MD, MPH, MMHC, discusses treatment selection in patients with metastatic hormone-sensitive prostate cancer.

November 22nd 2019, 12:37am

SMR Congress

Allison Betof Warner, MD, PhD, discusses the excitement surrounding the findings from the COMBI-i trial that was presented at the 2019 ASCO Annual Meeting. This trial investigated the combination of PD-1 inhibitor spartalizumab with dabrafenib plus trametinib in patients with advanced BRAF V6000mutant melanoma.

November 22nd 2019, 12:21am

SMR Congress

Alexander N. Shoushtari, MD, discusses the significance of the findings from the first-in-human trial evaluating tebentafusp, a TCR–CD3 bispecific, in patients with advanced melanoma.

November 20th 2019, 12:55am

State of the Science Summit on Genitourinary Cancers

Sam S. Chang, MD, MBA, discusses the shift toward personalized therapy in prostate cancer.

November 16th 2019, 2:51am

State of the Science Summit on Genitourinary Cancers

David Morris, MD, FACS, provides an update on the 3 newest agents available for nonmetastatic castration-resistant prostate cancer treatment and discussed factors to consider when choosing among them.

November 15th 2019, 1:08am

PER® New York Lung Cancer Symposium

Taofeek K. Owonikoko, MD, PhD, discusses current standard of care treatments for patients with small cell lung cancer.

November 14th 2019, 10:19pm

PER® New York Lung Cancer Symposium

Karen Kelly, MD, discusses how to determine treatment after patients with lung cancer progress on TKIs.